Fig 1: PROS1, PPBP, and LCN2 expression from PD patients and healthy controls. (A) The PROS1 expression in whole blood from PD (n = 16) was higher than HC (n = 16); (B) The PPBP expression in PBMC from PD (n = 22) was lower than HC (n = 16); (C) The LCN2 expression in PBMC from PD (n = 22) was higher than HC (n = 16). HC represents healthy controls, PD represents Parkinson’s disease. * p < 0.05, ** p < 0.01.
Fig 2: The expression levels of PPBP, PROS1 and LCN2 from PD patients and healthy controls in GSE100054. (A–C) The expression of PPBP, PROS1 and LCN2 in GSE100054. p < 0.05 was considered to be statistically different.
Fig 3: Receiver operating characteristic (ROC) curves of PPBP, ROS1, and LCN2. (A–C) The ROC of PPBP, ROS1, and LCN2. sensitivity (true-positive rate) and 1-specificity (false-positive rate); AUC: area under curve; CI: 95% confidence interval.
Fig 4: Plasma levels of PPBP, PROS1 and LCN2 in PD patients (n=69) and healthy controls (n=36). (A) Comparison of the expression levels of plasma PPBP; (B) Comparison of the expression levels of plasma PROS1; (C) Comparison of the expression levels of plasma LCN2. HC represents healthy controls, PD represents Parkinson’s disease. ** P < 0.01, **** P < 0.0001.
Supplier Page from CUSABIO Technology LLC for Human neutrophil activating protein-2,NAP-2 ELISA Kit